Navigation Links
Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
Date:12/6/2013

LONDON, Dec. 6, 2013 /PRNewswire/ -- Edison Investment Research's report, An intriguing PROSPECT, examines the long-term investment case for Bavarian Nordic, which rests on key value driver Prostvac, its Phase III prostate cancer vaccine.

Prostvac is well positioned to succeed where Provenge, the only approved prostate cancer vaccine, has so far failed. Final data from the pivotal Phase III PROSPECT trial are not due until 2016 but with enrolment on track to complete in H114, there is potential for interim analyses in 2015. PROSPECT data, coupled with read out of two Phase II Xtandi combination studies and an impressive 8.5-month overall survival benefit shown in the Phase II monotherapy trial, should help Bavarian Nordic secure a partner.

Its smallpox vaccine Imvamune is currently the revenue driver, with recurring revenues generated though supplies to the US government. Further orders are expected and new clinical data from 2016 should strengthen its market position, helping Bavarian Nordic towards sustainable and growing profitability.

Edison's healthcare team values the company at DKK2,965m, with potential for further upside.

For the full report see: www.edisoninvestmentresearch.com/research/company/bavarian-nordic  

About Edison Investment Research The launch of coverage on Bavarian Nordic is part of a programme of research initiations on biotech companies exposed to global market opportunities. Edison provides detailed research coverage on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. All reports Edison publishes are available to download free of charge from its website www.edisongroup.com.

Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities. For more information please contact:Lala GregorekEdison Investment Research+44 (0)20 3681 2527Robin DavisonEdison Investment Research+44 (0)20 3077 5737healthcare@edisongroup.comAbout Bavarian NordicBavarian Nordic is a Danish biotech focused on developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Its lead products are Prostvac (prostate cancer) and Imvamune (smallpox).


'/>"/>
SOURCE Edison Investment Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
2. Largest Global Survey Investigating Early Type 2 Diabetes Conversations Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation
3. Concord Medical Signs MOU with Shanghai New Hongqiao International Medical Center and GE Healthcare to Establish a Medical Imaging Diagnosis Center
4. Ansell Limited To Acquire BarrierSafe Solutions International
5. Archbishop Desmond Tutu Advocates St John International Charity Work on Packed London Visit and Audience with HM The Queen
6. Assurex Health Announces International Expansion through Canadian Partnership with the Centre for Addiction and Mental Health
7. Biotest Pharmaceuticals Honored with the 2013 Greater Miami Chamber of Commerce International Business Leadership Award for "Business Expansion"
8. Edison expands international bio-pharmaceutical presence with launch of coverage of Onconova Therapeutics
9. Philips Honored With Prestigious Respiratory Industry Excellence Award At AARC International Respiratory Congress
10. International Isotopes Inc. Announces Third Quarter And Nine Months 2013 Financial Results
11. New U.S. Patent Issued To Dyadic International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Aptuit, LLC, hat heute den ... Massachusetts General Hospital (MGH) unter Leitung von Dr. ... Identifizierung und Validierung neuartiger Targets in gramnegativen Bakterien.  Aptuit ... von Antibiotika bei der Behandlung schwerer Infektionen entgegenwirken können. ... ...
(Date:1/24/2017)... -- Laboratory Markets Limited has completed a comprehensive market ... both clinical and research laboratory settings. This study, which ... $6.8 billion and growing to $9.2 billion (CAGR of ... of mass spectrometry across more than 5,200 clinical and ... in the use of mass spectrometry in terms of ...
(Date:1/24/2017)... 2017 Global Market for Pharmaceutical ... A majority of medicines & drugs produced in ... (API), and such processes require alcoholic solvents such as ... of pharmaceutical solvents continues to be concentrated in the ... (APEJ) region as leading API suppliers and ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour ... in 2017. The entrepreneurs will showcase their businesses on February 6, 2017, at ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... today that its annual Solutions Series of webinars will start January 31 with ... discussing a number of current health and benefits topics, including employee engagement, pricing ...
(Date:1/24/2017)... ... January 24, 2017 , ... His message has been heard by more than ... End Distracted Driving , Joel Feldman, has reached his biggest national audience yet: the ... of the top newspapers in circulation in the country, and he hopes it will ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... Center ... 21st century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... center - as its Hispanic Leader of the Month. City of Hope is committed ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... is the focus of a new report from the Frank Hawkins Kenan ... School. , Influential business leaders, academics and policy makers identified concrete solutions at ...
Breaking Medicine News(10 mins):